Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

Msd R&d Co., Ltd.

Mds R&d (China) Co., Ltd.

Christopher J Sinz

Zhicai Wu

Alan C Cheng

Rongze Kuang

Song Yang

Maoqun Tian

Galen Paul Shearn-Nance

Jianming Bao

Ying-Duo Gao

Anthony K Ogawa

Zhiqiang Zhao

Jacqueline D Hicks

Phillip Patrick Sharp

Matthew J Lombardo

Donna A A W Hayes

Simon B Lang

Rohan Rajiv Merchant

Jovan Alexander Lopez

Brandon M Taoka

Salman Jabri

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Plasma kallikrein inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

Growing community of inventors

Walnut Creek, CA, United States of America

Christopher J Sinz